Lidex-E
Lidex-E - General Information
A topical glucocorticoid used in the treatment of eczema. [PubChem]
Pharmacology of Lidex-E
Lidex-E is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders such as eczema. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort. [Wikipedia]
Lidex-E for patients
Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions, especially under occlusive dressing.
5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
Lidex-E Interactions
No information provided.
Lidex-E Contraindications
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Additional information about Lidex-E
Lidex-E Indication: A topical anti-inflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Mechanism Of Action: Lidex-E is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders such as eczema. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort. Lidex-E binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Fluocinonide
Synonyms: Fluocinolide acetate; Fluocinolide; Fluocinolone acetonide acetate; Fluocinonide Emulsified Base; Fluocinonide [USAN-BAN-INN-JAN]; Fluocinonido [INN-Spanish]; Fluocinonidum [INN-Latin]
Drug Category: Anti-Allergic Agents; Anti-inflammatory Agents; Glucocorticoids
Drug Type: Small Molecule; Approved
Other Brand Names containing Fluocinonide: Bestasone; Biscosal; Cortalar; Fluzon; Lidex; Lidex E; Metosyn; Straderm; Synalar acetate; Topsymin; Topsyn; Vanos; Fluonex; Lidex-E; Lonide; Lyderm;
Absorption: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.
Toxicity (Overdose): Side effects may include acne-like eruptions, burning, dryness, excessive hair growth, infection of the skin, irritation, itching, lack of skin color, prickly heat, skin inflammation, skin loss or softening, stretch marks
Protein Binding: Not Available
Biotransformation: Primarily hepatic
Half Life: Not Available
Dosage Forms of Lidex-E: Gel Topical
Ointment Topical
Cream Topical
Chemical IUPAC Name: Not Available
Chemical Formula: C26H32F2O7
Fluocinonide on Wikipedia: https://en.wikipedia.org/wiki/Fluocinonide
Organisms Affected: Humans and other mammals
